Categories: US FDA Approval

US FDA withdraws approval for 2 Ranbaxy generic drugs

New Delhi, November 2014 –

The US Food and Drug Administration has rescinded approvals given to Ranbaxy Laboratories for two drugs in 2008, the company informed the Bombay Stock Exchange on Thursday.

The tentative nod given to Ranbaxy to manufacture and sell esomeprazole magnesium delayed-release capsules (20 mg and 40 mg) for heartburn and for anti-viral valganciclovir hydrochloride tablets (450 mg), in February and June of 2008, respectively, have been withdrawn since the regulator felt its decisions to grant approval were in error.

“FDA has said that its original decisions granting tentative approvals were in error because of the compliance status of the facilities referenced in the ANDAs at the time the tentative approvals were granted,” Ranbaxy said.

The company had received approval from FDA to launch the first generic versions of AstraZeneca’s heartburn medicine Nexium and Roche’s antiviral Valcyte. Ranbaxy had, as a result, a six-month period of exclusivity for launching the generic equivalent of Valcyte, which now stands cancelled.

AstraZeneca’s patent on Nexium ended in May this year, while Roche’s patent is to expire in March 2015. Roche had earlier challenged Ranbaxy when it had filed its ANDA for approval, citing alleged patent infringement on valganciclovir. Business Line

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago